Reduced- Compared with Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.

ABSTRACT:

Introduction

Reduced-dose direct oral anticoagulants (DOACs) may provide similar efficacy with less bleeding than standard dose for extended venous thromboembolism (VTE) treatment. It is unclear whether standard doses are preferable in certain subgroups.

Methods

We systematically searched MEDLINE, EMBASE, EMCARE, and Cochrane Central Register of Controlled Trials (CENTRAL) for randomized trials comparing reduced- with standard-dose DOACs for extended VTE treatment (registration number: INPLASY202550061). Outcomes included recurrent VTE, major bleeding, clinically relevant non-major bleeding (CRNMB), and mortality.

Results

Five trials (8,781 patients) were included. Reduced-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily, n  = 4,395), com

SUBMITTER: Cheung CKM 

PROVIDER: S-EPMC12908938 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature